Department of Medicine, Division of General Internal Medicine, Harborview Medical Center, University of Washington School of Medicine, Seattle, WA, USA.
University of Missouri - Kansas City School of Dentistry, Kansas City, MO, USA.
J Gen Intern Med. 2019 Dec;34(12):2749-2755. doi: 10.1007/s11606-019-05301-2. Epub 2019 Aug 29.
Despite known risks of using chronic opioid therapy (COT) for pain, the risks of discontinuation of COT are largely uncharacterized.
To evaluate mortality, prescription opioid use, and primary care utilization of patients discontinued from COT, compared with patients maintained on opioids.
Retrospective cohort study of patients with chronic pain enrolled in an opioid registry as of May 2010.
Patients with chronic pain enrolled in the opioid registry of a primary care clinic at an urban safety-net hospital in Seattle, WA.
Discontinuation from the opioid registry was the exposure of interest. Pre-specified main outcomes included mortality, prescription and primary care utilization data, and reasons for discontinuation. Data was collected through March 2015.
The study cohort comprised 572 patients with a mean age of 54.9 ± 10.1 years. COT was discontinued in 344 patients (60.1%); 254 (73.8%) discontinued patients subsequently filled at least one opioid prescription in Washington State, and 187 (54.4%) continued to visit the clinic. During the study period, 119 (20.8%) registry patients died, and 21 (3.7%) died of definite or possible overdose: 17 (4.9%) discontinued patients died of overdose, whereas 4 (1.75%) retained patients died of overdose. Most patients had at least one provider-initiated reason for COT discontinuation. Discontinuation of COT was associated with a hazard ratio for death of 1.35 (95% CI, 0.92 to 1.98, p = 0.122) and for overdose death of 2.94 (1.01-8.61, p = 0.049), after adjusting for age and race.
In this cohort of patients prescribed COT for chronic pain, mortality was high. Discontinuation of COT did not reduce risk of death and was associated with increased risk of overdose death. Improved clinical strategies, including multimodal pain management and treatment of opioid use disorder, may be needed for this high-risk group.
尽管已知慢性阿片类药物治疗(COT)用于疼痛存在风险,但 COT 停药的风险在很大程度上仍未得到充分描述。
评估与继续使用阿片类药物的患者相比,停止 COT 的患者的死亡率、处方类阿片药物使用和初级保健利用情况。
截至 2010 年 5 月,对西雅图一家城市医疗保障医院初级保健诊所的阿片类药物注册患者进行回顾性队列研究。
西雅图一家城市医疗保障医院初级保健诊所的阿片类药物注册患者。
停止使用阿片类药物注册是本研究的暴露因素。预先规定的主要结局包括死亡率、处方和初级保健使用数据以及停药原因。数据收集截至 2015 年 3 月。
该研究队列包括 572 名平均年龄为 54.9±10.1 岁的慢性疼痛患者。344 名患者(60.1%)停止接受 COT;254 名(73.8%)停止接受 COT 的患者随后在华盛顿州至少开了一种阿片类药物处方,187 名(54.4%)继续到诊所就诊。在研究期间,119 名(20.8%)登记患者死亡,21 名(3.7%)死于明确或可能的药物过量:17 名(4.9%)停止接受 COT 的患者死于药物过量,而 4 名(1.75%)继续接受 COT 的患者死于药物过量。大多数患者至少有一个由提供者发起的停止 COT 的原因。调整年龄和种族后,与 COT 停药相关的死亡风险比为 1.35(95%CI,0.92 至 1.98,p=0.122),药物过量死亡风险比为 2.94(1.01 至 8.61,p=0.049)。
在该队列中,接受 COT 治疗慢性疼痛的患者死亡率较高。停止 COT 并未降低死亡风险,反而增加了药物过量死亡的风险。对于这一高风险人群,可能需要改进包括多模式疼痛管理和治疗阿片类药物使用障碍在内的临床策略。